drugset / Trial / NCT04995120

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma

NCT04995120 ↗

Phase 2 Unknown 42 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to define whether combination of induction chemotherapy and PD-1 inhibitor (Toripalimab) improve the rate of larynx preservation, for patients with resectable laryngeal/hypopharyngeal carcinoma.

Timeline

Start
2021-04-07
Primary completion
2024-12-31
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 —
Subject Nab-paclitaxel Small molecule 260 mg/m2 —
Subject Paclitaxel Small molecule 175 mg/m2 —
Subject Toripalimab Monoclonal antibody 240 mg —